• On 27 June 2026, Ocular Therapeutix, Inc. (NasdaqGM: OCUL) was added to multiple Russell value benchmarks, including the Russell 3000 Value, 2000 Value, 2500 Value, 3000E Value, and Small Cap Comp Value indices.
• This broad Russell value index inclusion can increase visibility among institutional investors and passive funds that track these benchmarks, potentially reshaping how the market assesses Ocular Therapeutix's risk and exposure profile.
• We will now examine how Ocular Therapeutix's inclusion in multiple Russell value indices interacts with its existing investment narrative and outlook.

Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Ocular Therapeutix Investment Narrative Recap

To own Ocular Therapeutix, you need to believe AXPAXLI can clear clinical and regulatory hurdles in wet AMD and eventually support a viable commercial franchise, despite ongoing losses and dilution risk. The new Russell value index inclusions may broaden the shareholder base and improve liquidity, but they do not materially change the near term focus on SOL-1/SOL-R outcomes or the key risk that AXPAXLI stumbles before reaching the market.

The most relevant recent update here is the additional Week 52 data from the SOL-1 Phase 3 study in April 2026 and the plan to file an NDA based on those results. That clinical and regulatory path is central to any upside from increased index visibility, because investor interest from new funds will ultimately hinge on how convincingly AXPAXLI progresses from SOL-1 outcomes to an approved, adopted therapy in wet AMD.

Yet behind the index headlines, a less visible risk investors should be aware of is the company’s ongoing reliance on fresh capital and the possibility that...

Ocular Therapeutix's narrative projects $335.8 million revenue and $65.7 million earnings by 2029. This requires 86.2% yearly revenue growth and an earnings increase of about $356 million from -$290.5 million today.

Uncover how Ocular Therapeutix's forecasts yield a $26.00 fair value, a 165% upside to its current price.

Exploring Other Perspectives

Some of the highest target analysts were assuming revenue could reach about US$593.3 million by 2029, which is far more optimistic than consensus and could look very different once the impact of this new index inclusion and ongoing dilution risk is reassessed.

Explore 5 other fair value estimates on Ocular Therapeutix - why the stock might be worth over 10x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Ocular Therapeutix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ocular Therapeutix's overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• Find 43 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.